OBSOLETE: Primary peritoneal serous/papillary carcinoma Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Dec 2025Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

University of Colorado, Denver — PHASE1

TrialRECRUITING

Aug 2025A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Sichuan Baili Pharmaceutical Co., Ltd. — PHASE3

TrialRECRUITING

Jul 2025A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

AbbVie — PHASE2

TrialRECRUITING

Jun 2025Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma

Centre Oscar Lambret — NA

TrialRECRUITING

Mar 2024Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

GOG Foundation — PHASE3

TrialRECRUITING

Nov 2022Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy

Gangnam Severance Hospital — NA

TrialRECRUITING

Sep 2022Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

AbbVie — PHASE2

TrialACTIVE NOT RECRUITING

Aug 2022Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation — PHASE3

TrialRECRUITING

Jun 2022Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

The Netherlands Cancer Institute — PHASE2

TrialACTIVE NOT RECRUITING

Aug 2016Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for OBSOLETE: Primary peritoneal serous/papillary carcinoma.
Check the disease page for updates →

Clinical Trial Landscape

10 active trials

3Phase 3

3Phase 2

1Phase 1

2N/A

1Unknown

10Total recruiting

Search clinical trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Primary peritoneal serous/papillary carcinoma.
Search PubMed for OBSOLETE: Primary peritoneal serous/papillary carcinoma →

Browse all OBSOLETE: Primary peritoneal serous/papillary carcinoma news →

Specialist Network

No specialists currently listed for OBSOLETE: Primary peritoneal serous/papillary carcinoma.

View all OBSOLETE: Primary peritoneal serous/papillary carcinoma specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰